Dr. Ku on Combinations and Sequencing of Treatments for Gastric Cancer

Geoffrey Y. Ku, MD
Published: Monday, Jan 23, 2017



Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations and sequencing of treatments for patients with gastric and esophageal cancers.

Patients getting the treatment in the third-line setting is too late, explains Ku. There are 10 other phase III studies that are evaluating treatment in the first- and second-line setting.

Another area of improvement is biomarker selection. Up until this point, the main biomarker has been PD-L1 expression on the tumor cells; however, it’s not perfect, Ku states. When PD-L1 is used as a biomarker, PD-L1–positive tumors respond approximately 25% of the time, whereas PD-L1–negative tumors respond 10% of the time.
 
SELECTED
LANGUAGE


Geoffrey Y. Ku, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combinations and sequencing of treatments for patients with gastric and esophageal cancers.

Patients getting the treatment in the third-line setting is too late, explains Ku. There are 10 other phase III studies that are evaluating treatment in the first- and second-line setting.

Another area of improvement is biomarker selection. Up until this point, the main biomarker has been PD-L1 expression on the tumor cells; however, it’s not perfect, Ku states. When PD-L1 is used as a biomarker, PD-L1–positive tumors respond approximately 25% of the time, whereas PD-L1–negative tumors respond 10% of the time.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x